Cargando…
ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
Activation of cancer stem cell signaling is central to acquired resistance to therapy in esophageal cancer (EC). ABT-263, a potent Bcl-2 family inhibitor, is active against many tumor types. However, effect of ABT-263 on EC cells and their resistant counterparts are unknown. Here we report that ABT-...
Autores principales: | Chen, Qiongrong, Song, Shumei, Wei, Shaozhong, Liu, Bin, Honjo, Soichiro, Scott, Ailing, Jin, Jiankang, Ma, Lang, Zhu, Haitao, Skinner, Heath D., Johnson, Randy L., Ajani, Jaffer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694873/ https://www.ncbi.nlm.nih.gov/pubmed/26317542 |
Ejemplares similares
-
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer
por: HONJO, SOICHIRO, et al.
Publicado: (2014) -
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
por: Yang, Xiaolan, et al.
Publicado: (2021) -
JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017) -
Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
por: Lee, Anbok, et al.
Publicado: (2021) -
Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells
por: Sato, Kota, et al.
Publicado: (2021)